8-K - Design Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Design Therapeutics' Board appointed David Shapiro, M.D. as a Class III director effective March 31, 2026, with committee role and standard compensation under non-employee director policy.

Key Takeaways

1David Shapiro, M.D. appointed to Board as Class III director effective March 31, 2026, term ends at 2027 annual meeting.

2Appointed to Nominating and Corporate Governance Committee.

3Annual cash retainers: $40,000 for Board service, $5,000 for Nominating Committee.

4Initial option grant for 60,000 shares, vesting monthly over three years.

5Prorated annual option grant for 7,500 shares, vesting monthly over one year.

6Entered standard indemnification agreement for directors and officers.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | |---|---|

Management Change

$40.0K$5.0K

Executive & Director Changes

David Shapiro, M.D.

Class III director and Nominating and Corporate Governance Committee member

appointed

Effective: 2026-03-31

Exhibits (1)

8-K